Developing innovative medicines for diseases with unmet need

Karus Therapeutics is investing in innovative next generation brain-penetrant HDAC6 inhibitors developed from our in-house chemistry. We have clinical assets available for partnering.

Our team

Our highly experienced management team has a track record of business, scientific and clinical excellence in small molecule drug design and development. Our programmes are underpinned by a broad, wholly-owned, intellectual property estate.

Our approach

Our orally-active small molecule drugs have been designed and developed to be highly-selective therapies for patients with unmet clinical need and limited treatment options.


We invest in research and development of the highest quality and collaborate with leading commercial and academic centres of excellence. Our R&D programme is focused on next generation brain-penetrant small molecules for the treatment of glioblastoma and other indications.

Clinical assets

We have completed a Phase I study of KA2237, a PI3K β/δ isoform-selective inhibitor, in patients with relapsed/refractory B cell lymphoma. KA2237 showed an overall response rate of 50% in evaluable patients treated with a starting dose that matched or exceeded the RP2D.

We have completed a Phase I study of KA2507, a selective HDAC6 inhibitor, in patients with solid tumours, in which KA2507 showed excellent tolerability.

Strategic partnering

We are seeking strategic collaborations with leading pharma and biotech companies who are developing and commercialising innovative therapeutics.


We are supported by a syndicate of world-class life science investors from the US and Europe, including SV Health Investors, New Leaf Venture Partners and Novo Ventures.